The producer of generic drugs recorded a profit before tax of RM69.5 million for the quarter ended Sept 30, 2022 (Q3 2022), a 5.54% rise from the same quarter of the previous financial year.

For the same quarter, cumulative revenue was RM544.76 million, a 10.33% increase over the same period last year.

The company also announced an interim dividend of 0.5 sen per share, amounting to RM4.76 million, to be paid to shareholders in the final quarter of the financial year.

Group managing director Leonard Ariff Abdul Shatar said the outlook for the company was positive “in light of the continuous emphasis placed by the government on the healthcare sector”.

He said Duopharma would continue to explore new opportunities to expand its portfolio of products in the health and wellness sector while strengthening its commitment in the halal sector.

Under a deal signed recently with SCM Lifesciences, a Duopharma subsidiary, Duopharma Consumer Healthcare Sdn Bhd, will distribute the South Korean company’s halal-certified anti-hair loss products specifically formulated for the Malaysian market.